about
Nivolumab in previously untreated melanoma without BRAF mutationComparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL StudyThe Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis.Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer.Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.Diagnostic and therapeutic quandaries in primary manifestation of Hodgkin's disease in the central nervous system.Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome.Chemotherapy treatment patterns and neutropenia management in gastric cancer.Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma.Guidelines for the diagnosis and management of osteoporosis in Poland : Update 2017.Prevalence of rare EGFR gene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patients.Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer.Beyond PD-L1 Markers for Lung Cancer ImmunotherapyImmunogenicity of influenza vaccination in patients with non-Hodgkin lymphomaRandomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma ResearchCorrelation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patientsHuman leukocyte antigen-G polymorphisms influence the clinical outcome in diffuse large B-cell lymphomaDoes diabetes alter the risk of neoplasms? Real-world data analysis in Poland: incidence rates for selected neoplasms in patients with diabetesEfficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based ChemotherapyPopulation morbidity in elderly lung cancer patients from Poland with specific trends in elderly women
P50
Q29620688-E7A0BC9A-ED51-4305-BF80-9D71D5F43683Q33751194-6F58F228-B934-429C-AB7E-E156BB385020Q34491507-9BD1E1A1-9678-41C9-93FD-962B17A321BBQ36107363-A9DCC04A-A01F-48CB-AEDD-0D27FE483B80Q36243957-D82F1DED-82B2-435B-9751-A40CB6BF7321Q36378565-2F53621B-2097-4E56-8098-219A73F45F32Q37601946-E0E1AC74-EBBB-47EE-9D2E-8B6E384E950DQ38405004-60397E6C-FD37-431B-8222-901F5042F441Q38815778-5B18C7DD-83A4-462C-9F40-33C04CD0A8A0Q40694392-7A5A9A82-EA00-4FB4-A152-A037839741B2Q41050317-07F325BD-3607-4045-B72D-F5B70BDCD06FQ42521703-72EA076A-07D1-4F83-9515-0B52E53E0EA9Q44452652-DD5ADD42-F4D3-4879-8D6B-D58723D8DFCFQ46057636-AB740824-1673-4D87-94EA-60D84609035DQ47686349-A0CF62F5-225D-417B-990B-65227B99BB52Q47844224-3AC1AC44-4770-4786-BCD4-6C3BDD4A161AQ48592207-3CD10CC7-370D-4365-9F28-A1A5EAB372EAQ55036457-94B975CA-071C-4FF5-8066-75793A8B2387Q55058950-E38449F5-C65A-4F62-B4DE-E2D7BE7F3116Q64252367-976D7FCE-886D-4411-A23B-B3FF9C0E2E01Q79898425-FF966ED2-8559-4109-853C-3A296FEE257DQ81251714-B8E5541A-26CB-46DE-8681-AD69F0959EE4Q85359341-F9B467C2-2F80-4B70-B690-29DD9F354310Q86596576-3B79BAA6-A4AA-4EA8-917D-5D24CC5E8FADQ87787325-6E0DBFB9-E9D9-4982-8C68-64BB6E584290Q91696632-E31A8990-E2BB-4DB0-8204-623E3D4F4DABQ92898469-3D3F6511-6BA6-4015-900D-374C494ABD40
P50
description
researcher ORCID ID = 0000-0003-4791-8372
@en
wetenschapper
@nl
name
Ewa Kalinka-Warzocha
@ast
Ewa Kalinka-Warzocha
@en
Ewa Kalinka-Warzocha
@es
Ewa Kalinka-Warzocha
@nl
type
label
Ewa Kalinka-Warzocha
@ast
Ewa Kalinka-Warzocha
@en
Ewa Kalinka-Warzocha
@es
Ewa Kalinka-Warzocha
@nl
prefLabel
Ewa Kalinka-Warzocha
@ast
Ewa Kalinka-Warzocha
@en
Ewa Kalinka-Warzocha
@es
Ewa Kalinka-Warzocha
@nl
P1153
16052770000
P31
P496
0000-0003-4791-8372